Table 1.
Pharmacological comparison of Gs and Golf engagement in D1R
| D1L_GsV | D1L_GolfV | |||
|---|---|---|---|---|
| EC50 (nM) | Emax (%) | EC50 (nM) | Emax (%) | |
| DA | 49.0 ± 4.3 | 100.0 ± 1.3 | 111.9 ± 25.4 | 100.0 ± 3.9 |
| NE | 1002.3 ± 116.3c | 99.2 ± 2.2 | 2280.3 ± 784.5c | 97.8 ± 7.9 |
| SKF38393 | 25.1 ± 4.0 | 61.6 ± 1.3c | 40.6 ± 14.6 | 62.1 ± 4.2c |
| SKF81297 | 5.4 ± 1.2c | 95.0 ± 2.7 | 32.6 ± 12.7 | 98.8 ± 7.4 |
| SKF82958 | 0.2 ± 0.1c | 101.5 ± 5.2 | 0.1 ± 0.1c | 107.6 ± 11.0 |
| NPA | 145.5 ± 19.5b | 111.9 ± 2.4b | 34.7 ± 17.3 | 67.9 ± 6.7b |
| DHX | 24.3 ± 3.5 | 121.3 ± 2.7c | 13.4 ± 8.0a | 39.0 ± 6.1c |
| A77636 | 0.5 ± 0.1c | 102.5 ± 3.8 | 0.7 ± 0.2c | 113.4 ± 5.6 |
Data were fit by non-linear regression to a sigmoidal dose-response relationship against the agonist concentration. EC50 and Emax values are means ± S.E.M. of more than five experiments performed in triplicate. Emax values are expressed in % normalized to dopamine results
a p < 0.05
b p < 0.01
c p < 0.001 compared with DA (one-way analysis of variance, followed by post hoc Tukey test)